Home » Healthcare » Checkpoint Inhibitor Refractory Cancer Market

Global Checkpoint Inhibitor Refractory Cancer Market By Type (CTLA-4 Inhibitor, PD-1 Inhibitor, PD-L1 Inhibitor, Others)By Wound Type (Lung Cancer, Bladder Cancer, Other) Growth, Future Prospects & Competitive Analysis, 2016 – 2030

Published: | Report ID: 16811 | Report Format : PDF

Key Highlights of the report

How are the major segments performing in the Checkpoint Inhibitor Refractory Cancer market?

  • The checkpoint inhibitor refractory cancer market’s CTLA-4 Inhibitor category had the biggest market share in 2022 and is projected to grow at the quickest rate during the forecast period.
  • In 2022, the Lung Cancer segment held the largest proportion. One of the main drivers for the segment is the rising number of lung cancer cases.

What is the Market Size of Checkpoint Inhibitor Refractory Cancer regarding value?

The global checkpoint inhibitor refractory cancer market is anticipated to grow at a substantial CAGR of xx% in the upcoming years. The global wound care biologics industry was estimated to be worth USD xx million in 2022 and was expected to be worth USD xx million by 2028.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample
CTA Design Element 3

Which region dominated the checkpoint inhibitor refractory cancer market?

In 2022, it was anticipated that North America’s Checkpoint Inhibitor Refractory Cancer Market would hold the biggest market share at 39%. The checkpoint inhibitor refractory cancer market in North America is anticipated to increase due to factors including positive regulatory actions by the local regulatory authorities, particularly in the United States, and rising cancer prevalence. For instance, several cancers are treated with these inhibitors. According to the American Cancer Society, 1.9 million new instances of cancer will be diagnosed, and 609,360 people will die from cancer in the United States in 2022. Consequently, it is projected to increase the market’s revenue share in the area.

How is US Market Performing in the checkpoint inhibitor refractory cancer market?

In 2022, it was predicted that the US would have 99.2% of the market for checkpoint inhibitors in North America. The considerable portion in the US is mostly explained by the region’s increasing prevalence of several chronic diseases that call for effective treatment, such as urothelial carcinomas, lung malignancies, skin cancers, and diabetes.

How is the economy impacting global checkpoint inhibitor refractory cancer growth?

Growing inflation rates in several countries have considerably impacted consumers’ purchasing power. During a recession, people prioritize their needs, which may affect the purchases they make. Additionally, market liquidity may decline. The Russia-Ukraine War caused great harm to nations that purchased goods from Russia and Ukraine. Doctors may decide against unnecessary operations to treat patients with Covid-19 infections effectively due to the Covid-19 pandemic. Therefore, each of these elements can potentially restrict the market growth.

What is the competitive environment of the checkpoint inhibitor refractory cancer market?

The market is currently fragmented, and many players are entering the market. Most companies are using new technologies and strategies to expand their market shares. Players in the checkpoint inhibitor refractory cancer market are heavily committing to extensive R&D projects to introduce novel products and offer trustworthy services. Expansion of the product portfolio, mergers, and acquisitions are common significant strategies key players use.

Executive Summary

What are the key trends in the Checkpoint Inhibitor Refractory Cancer market?

  • According to variables, including the rise in the number of FDA approvals for clinical therapy with checkpoints (PD1/PDL1) inhibitors, the market for checkpoint inhibitors for cancer patients with refractory disease is anticipated to develop throughout the analysis period.
  • As early diagnosis continues to be the key to cancer control, the expansion of cancer awareness campaigns is anticipated to increase the population’s access to support, attention, early diagnosis, treatment, and palliative care.

What is the market scenario of the Checkpoint Inhibitor Refractory Cancer Market?

Antibody Checkpoint Drugs are called inhibitors to prevent immunological checkpoints. These medications prevent them, allowing immune cells to react forcefully to malignancy. The T-cells can attack cancer cells since this stops the “off” signal from being sent. Checkpoint inhibitors can treat various malignancies, including lung cancer (NSCLC and SCLC), melanoma, triple-negative breast cancer, Hodgkin lymphoma, urothelial carcinoma, renal cell cancer (RCC), and many more. Immune checkpoint inhibitors have an advantage over other commonly used therapeutic methods like chemotherapy because of their longer half-life and potent anti-cancer activity.

Which are the key investments by the checkpoint inhibitor refractory cancer market players?

Key players are implementing various methods, including product launches, alliances, and mergers and acquisitions, to strengthen their position in the business. For instance, Merck reported that KEYTRUDA, an anti-PD-1 treatment, had received FDA permission to be used in combination with chemotherapy, either with bevacizumab or without it, in October 2021. The medicine is used to treat cervical cancer patients with tumors exhibiting PD-L1 (Combined Positive Score [CPS] 1) as found by an FDA-approved test and with persistent, recurring, or metastatic disease. Novartis International AG purchased the Medicines Company in January 2020. With a vaccine-like strategy, this acquisition aided Novartis in treating the top cause of mortality and disability in the world.

Some major checkpoint inhibitor refractory cancer market players are 4D PHARMA PLC, 4SC AG, ASCENTAGE PHARMA GROUP, EISAI INC, Bristol-Myers Squibb, AstraZeneca, and Merck.

What are the Major Driving Factors for the Checkpoint Inhibitor Refractory Cancer Market?

The significant rise in the global prevalence of numerous malignancies, particularly in emerging and developed economies, is one of the main drivers driving the market’s growth. Another important aspect is the aging population around the world. For instance, according to the World Health Organization, cancer is now the leading cause of death worldwide. According to the latest Globocan study published by the International Agency for Research on Cancer (IARC) in December 2020, there will be 10.3 million more cancer-related deaths worldwide in 2020 than in 2009. As a result, an increase in the patient pool’s size increases demand for the market.

What are the Major Risks for the Checkpoint Inhibitor Refractory Cancer Market?

Laboratory tests, hospital stays, and innovative checkpoint inhibitors (PD-1 and PD-L1) inhibitor medications contribute to the high cost of cancer therapy. The cost of these medicines varies according to the stage of the malignancy. Growth in the demand for alternative treatment methods like operations is also attributed to the high expense. For instance, the cost of cancer treatment in India ranges from INR 90,561 (US$ 1,134) to INR 27,67,149, with an average cost of INR 503,118 (US$ 6,300). (USD 34,650). Additionally, checkpoint inhibitors are expensive when purchased. Consequently, the high price of cancer therapy restricts market expansion.

Which is the key application in the checkpoint inhibitor refractory cancer market?

According to the application, the Lung Cancer segment dominates the worldwide Checkpoint Inhibitor Refractory Cancer market with a share of 37%. Most leading companies are focusing on the ongoing development of advanced treatments and enhancing the efficacy of the currently available therapeutics due to the substantial prevalence of lung cancer. An increase is also aiding the expansion of the lung cancer market in diagnosing NSCLC (non-small cell lung cancer) and raising awareness in developing and developed economies.

How is the checkpoint inhibitor refractory cancer market performing in regions?

The market for checkpoint inhibitor-resistant cancer is expected to have the largest share in 2022, accounting for 39% of global sales. The market for checkpoint inhibitors for refractory cancer in North America is expected to grow due to several factors, including favorable regulatory actions by the local regulatory authorities, primarily in the United States, and a rise in the prevalence of cancer. For instance, these inhibitors are used to treat a variety of malignancies. In the United States, there will be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in 2022, according to the American Cancer Society. It is anticipated that this will lead to a rise in the market’s revenue share in the region.

In 2022, the Asia Pacific Checkpoint Inhibitor Refractory Cancer Market was anticipated to reach a market share of 37%. The high incidence of cancer, growing government involvement to increase cancer diagnosis, increasing adoption of inorganic growth strategies like collaborations, acquisitions, and mergers by major players operating in the market introduction of new immunotherapies with fewer side effects, and growing geriatric population in this region, especially in India, are all factors that have contributed to the region’s growth. For instance, according to the Indian Council of Medical Research’s report on cancer, the number of cases in India could rise by 12% over the next five years, reaching 1.5 million instances by 2025, up from 1.39 million in 2020. This is a significant factor that will encourage market expansion.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

What are the major players planning for the future of the checkpoint inhibitor refractory cancer market?

Intolerant to Checkpoint Inhibitors Cancer To gauge the interest of potential patients and build a larger clientele, market startup players are utilizing various marketing methods, including new product launches, geographic expansion, mergers and acquisitions, partnerships, and collaboration. For instance, ALX Oncology, a company that developed immuno-oncology treatments for cancer treatment, was established in 2015. Checkpoint inhibitor ALX148, the leading product candidate, consists of an affinity CD47 binding SIRP domain connected to an inactive Fc region of a human immunoglobulin. By attaching to CD47, it blocks the CD47-SIRP signaling pathway.

REPORT ATTRIBUTE DETAILS
Checkpoint Inhibitor Refractory Cancer Market by Volume Yes
Checkpoint Inhibitor Refractory Cancer Market by Value Yes
Checkpoint Inhibitor Refractory Cancer Market, Tornado Analysis Yes
Checkpoint Inhibitor Refractory Cancer Market, STAR Analysis Yes
Checkpoint Inhibitor Refractory Cancer Market, SRC Analysis Yes
Checkpoint Inhibitor Refractory Cancer Market, Import-Export Data Yes (On Demand)
Checkpoint Inhibitor Refractory Cancer Market Pricing Analysis Yes (On Demand)
Checkpoint Inhibitor Refractory Cancer Market Segment Analysis By Type (CTLA-4 Inhibitor, PD-1 Inhibitor, PD-L1 Inhibitor and Others)

By Application (Lung Cancer, Bladder Cancer and Other)

Checkpoint Inhibitor Refractory Cancer Market, Regional Analysis  North America (US and Canada)

Europe (Germany, UK, France, Italy, Spain, and Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, South East Asia, and Rest of Asia Pacific)

Latin America (Brazil, Mexico, and Rest of Latin America)

Middle East and Africa (GCC Countries, South Africa, and Rest of Middle East and Africa)

Checkpoint Inhibitor Refractory Cancer Market Key Companies 4D PHARMA PLC, 4SC AG, ASCENTAGE PHARMA GROUP, EISAI INC, Bristol-Myers Squibb, AstraZeneca and Merck
Checkpoint Inhibitor Refractory Cancer Market Competitive Landscape Market Share Analysis

Competitive Benchmarking

Key Players Market Positioning

Geographical Presence Analysis

Major Strategies Adopted

Segmentation of Global Checkpoint Inhibitor Refractory Cancer Market-

Global Checkpoint Inhibitor Refractory Cancer Market – By Type

  • CTLA-4 Inhibitor
  • PD-1 Inhibitor
  • PD-L1 Inhibitor
  • Others

Global Checkpoint Inhibitor Refractory Cancer Market – By Wound Type

  • Lung Cancer
  • Bladder Cancer
  • Other

Global Checkpoint Inhibitor Refractory Cancer Market – By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Approach Adopted
1.3.4.1. Top-Down Approach
1.3.4.2. Bottom-Up Approach
1.3.5. Assumptions
1.4. Market Introduction
1.5. Market Research Scope

2. Executive Summary
2.1. Market Snapshot: Global Checkpoint Inhibitor Refractory Cancer Market
2.2. Global Checkpoint Inhibitor Refractory Cancer Market, By Type
2.3. Global Checkpoint Inhibitor Refractory Cancer Market, By Application
2.4. Global Checkpoint Inhibitor Refractory Cancer Market, By Region

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Checkpoint Inhibitor Refractory Cancer Market Value, 2017-2030, (US$ Bn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Key Growth Trends
3.2.2. Market Drivers
3.2.3. Market Restraints
3.2.4. Market Opportunities
3.2.5. Major Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Application
3.5.2. Type
3.5.3. Geography

4. Premium Insights
4.1. STAR (Situation, Task, Action, Results) Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers/Consumers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitute Types
4.2.5. Intensity of Competitive Rivalry
4.3. Key Market Trends
4.3.1. Demand Side Trends
4.3.2. Supply Side Trends
4.4. Value Chain Analysis
4.5. Technology Analysis
4.6. Analysis and Recommendations
4.7. Marketing Strategy Analysis
4.7.1. Direct Marketing
4.7.2. Indirect Marketing
4.7.3. Marketing Channel Development Trend

5. Market Positioning of Key Players, 2022
5.1. Company market share of key players, 2022
5.2. Competitive Benchmarking
5.3. Market Positioning of Key Vendors
5.4. Geographical Presence Analysis
5.5. Major Strategies Adopted by Key Players
5.5.1. Key Strategies Analysis
5.5.2. Mergers and Acquisitions
5.5.3. Partnerships
5.5.4. Type Launch
5.5.5. Geographical Expansion
5.5.6. Others

6. COVID 19 Impact Analysis
6.1. Global Checkpoint Inhibitor Refractory Cancer Market Pre Vs Post COVID 19, 2022 – 2030
6.2. Impact on Import & Export
6.3. Impact on Demand & Supply

7. Global Checkpoint Inhibitor Refractory Cancer Market
7.1. Global Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030(US$ Bn)
7.1.1. Overview
7.1.2. Global Checkpoint Inhibitor Refractory Cancer Market, By Type, 2022 vs 2030 (in%)
7.1.3. Global Checkpoint Inhibitor Refractory Cancer Market, By CTLA-4 Inhibitor, 2017-2030 (US$ Bn)
7.1.4. Global Checkpoint Inhibitor Refractory Cancer Market, By PD-1 Inhibitor, 2017-2030 (US$ Bn)
7.1.5. Global Checkpoint Inhibitor Refractory Cancer Market, By PD-L1 Inhibitor, 2017-2030 (US$ Bn)
7.1.6. Global Checkpoint Inhibitor Refractory Cancer Market, By Others, 2017-2030 (US$ Bn)
7.2. Global Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030(US$ Bn)
7.2.1. Overview
7.2.2. Global Checkpoint Inhibitor Refractory Cancer Market, By Application, 2022 vs 2030 (in%)
7.2.3. Global Checkpoint Inhibitor Refractory Cancer Market, By Lung Cancer, 2017-2030 (US$ Bn)
7.2.4. Global Checkpoint Inhibitor Refractory Cancer Market, By Bladder Cancer, 2017-2030 (US$ Bn)
7.2.5. Global Checkpoint Inhibitor Refractory Cancer Market, By Others, 2017-2030 (US$ Bn)

8. North America Checkpoint Inhibitor Refractory Cancer Market Analysis
8.1. North America Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030(US$ Bn)
8.1.1. Overview
8.1.2. SRC Analysis
8.2. North America Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030(US$ Bn)
8.2.1. Overview
8.2.2. SRC Analysis
8.3. North America Checkpoint Inhibitor Refractory Cancer Market, by Country, 2017-2030 (US$ Bn)
8.3.1. U.S.
8.3.1.1. U.S. Checkpoint Inhibitor Refractory Cancer Market Estimates and Forecast, 2017-2030 (US$ Bn)
8.3.1.2. U.S. Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
8.3.1.3. U.S. Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
8.3.2. Canada
8.3.2.1. Canada Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
8.3.2.2. Canada Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)

9. Europe Checkpoint Inhibitor Refractory Cancer Market Analysis
9.1. Europe Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030(US$ Bn)
9.1.1. Overview
9.1.2. SRC Analysis
9.2. Europe Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030(US$ Bn)
9.2.1. Overview
9.2.2. SRC Analysis
9.3. Europe Checkpoint Inhibitor Refractory Cancer Market, by Country, 2017-2030 (US$ Bn)
9.3.1. Germany
9.3.1.1. Germany Checkpoint Inhibitor Refractory Cancer Market Estimates and Forecast, 2017-2030 (US$ Bn)
9.3.1.2. Germany Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
9.3.1.3. Germany Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
9.3.2. France
9.3.2.1. France Checkpoint Inhibitor Refractory Cancer Market Estimates and Forecast, 2017-2030 (US$ Bn)
9.3.2.2. France Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
9.3.2.3. France Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
9.3.3. UK
9.3.3.1. UK Checkpoint Inhibitor Refractory Cancer Market Estimates and Forecast, 2017-2030 (US$ Bn)
9.3.3.2. UK Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
9.3.3.3. UK Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
9.3.4. Italy
9.3.4.1. Italy Checkpoint Inhibitor Refractory Cancer Market Estimates and Forecast, 2017-2030 (US$ Bn)
9.3.4.2. Italy Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
9.3.4.3. Italy Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
9.3.5. Spain
9.3.5.1. Spain Checkpoint Inhibitor Refractory Cancer Market Estimates and Forecast, 2017-2030 (US$ Bn)
9.3.5.2. Spain Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
9.3.5.3. Spain Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
9.3.6. Rest of Europe
9.3.6.1. Rest of Europe Checkpoint Inhibitor Refractory Cancer Market Estimates and Forecast, 2017-2030 (US$ Bn)
9.3.6.2. Rest of Europe Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
9.3.6.3. Rest of Europe Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)

10. Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Analysis
10.1. Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030(US$ Bn)
10.1.1. Overview
10.1.2. SRC Analysis
10.2. Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030(US$ Bn)
10.2.1. Overview
10.2.2. SRC Analysis
10.3. Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, by Country, 2017-2030 (US$ Bn)
10.3.1. China
10.3.1.1. China Checkpoint Inhibitor Refractory Cancer Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.3.1.2. China Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
10.3.1.3. China Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
10.3.2. Japan
10.3.2.1. Japan Checkpoint Inhibitor Refractory Cancer Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.3.2.2. Japan Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
10.3.2.3. Japan Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
10.3.3. India
10.3.3.1. India Checkpoint Inhibitor Refractory Cancer Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.3.3.2. India Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
10.3.3.3. India Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
10.3.4. South Korea
10.3.4.1. South Korea Checkpoint Inhibitor Refractory Cancer Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.3.4.2. South Korea Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
10.3.4.3. South Korea Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
10.3.5. South-East Asia
10.3.5.1. South-East Asia Checkpoint Inhibitor Refractory Cancer Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.3.5.2. South-East Asia Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
10.3.5.3. South-East Asia Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
10.3.6. Rest of Asia Pacific
10.3.6.1. Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.3.6.2. Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
10.3.6.3. Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)

11. Latin America Checkpoint Inhibitor Refractory Cancer Market Analysis
11.1. Latin America Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030(US$ Bn)
11.1.1. Overview
11.1.2. SRC Analysis
11.2. Latin America Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030(US$ Bn)
11.2.1. Overview
11.2.2. SRC Analysis
11.3. Latin America Checkpoint Inhibitor Refractory Cancer Market, by Country, 2017-2030 (US$ Bn)
11.3.1. Brazil
11.3.1.1. Brazil Checkpoint Inhibitor Refractory Cancer Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.1.2. Brazil Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
11.3.1.3. Brazil Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
11.3.2. Mexico
11.3.2.1. Mexico Checkpoint Inhibitor Refractory Cancer Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.2.2. Mexico Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
11.3.2.3. Mexico Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
11.3.3. Rest of Latin America
11.3.3.1. Rest of Latin America Checkpoint Inhibitor Refractory Cancer Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.3.2. Rest of Latin America Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
11.3.3.3. Rest of Latin America Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)

12. Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market Analysis
12.1. Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030(US$ Bn)
12.1.1. Overview
12.1.2. SRC Analysis
12.2. Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030(US$ Bn)
12.2.1. Overview
12.2.2. SRC Analysis
12.3. Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, by Country, 2017-2030 (US$ Bn)
12.3.1. GCC Countries
12.3.1.1. GCC Countries Checkpoint Inhibitor Refractory Cancer Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.1.2. GCC Countries Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
12.3.1.3. GCC Countries Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
12.3.2. South Africa
12.3.2.1. South Africa Checkpoint Inhibitor Refractory Cancer Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.2.2. South Africa Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
12.3.2.3. South Africa Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
12.3.3. Rest of Middle East and Africa
12.3.3.1. Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.3.2. Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
12.3.3.3. Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)

13. Company Profiles
13.1. 4D PHARMA PLC
13.1.1. Company Overview
13.1.2. Types/Services Portfolio
13.1.3. Geographical Presence
13.1.4. Financial Summary
13.1.4.1. Market Revenue and Net Profit (2019-2022)
13.1.4.2. Business Segment Revenue Analysis
13.1.4.3. Geographical Revenue Analysis
13.2. 4SC AG
13.3. ASCENTAGE PHARMA GROUP
13.4. EISAI INC
13.5. Bristol-Myers Squibb
13.6. AstraZeneca
13.7. Merck
13.8. Others

List of Figures
FIG. 1 Global Checkpoint Inhibitor Refractory Cancer Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Checkpoint Inhibitor Refractory Cancer Market Segmentation
FIG. 4 Global Checkpoint Inhibitor Refractory Cancer Market, By Type, 2022 (US$ Bn)
FIG. 5 Global Checkpoint Inhibitor Refractory Cancer Market, By Application, 2022 (US$ Bn)
FIG. 6 Global Checkpoint Inhibitor Refractory Cancer Market, by Geography, 2022 (US$ Bn)
FIG. 7 Attractive Investment Proposition, By Type, 2022
FIG. 8 Attractive Investment Proposition, By Application, 2022
FIG. 9 Attractive Investment Proposition, by Geography, 2022
FIG. 10 Global Market Share Analysis of Key Checkpoint Inhibitor Refractory Cancer Market Manufacturers, 2022
FIG. 11 Global Market Positioning of Key Checkpoint Inhibitor Refractory Cancer Market Manufacturers, 2022
FIG. 12 Global Checkpoint Inhibitor Refractory Cancer Market Value Contribution, By Type, 2022 & 2028 (Value %)
FIG. 13 Global Checkpoint Inhibitor Refractory Cancer Market, By CTLA-4 Inhibitor, Value, 2017-2030 (US$ Bn)
FIG. 14 Global Checkpoint Inhibitor Refractory Cancer Market, By PD-1 Inhibitor, Value, 2017-2030 (US$ Bn)
FIG. 15 Global Checkpoint Inhibitor Refractory Cancer Market, By PD-L1 Inhibitor, Value, 2017-2030 (US$ Bn)
FIG. 16 Global Checkpoint Inhibitor Refractory Cancer Market, By Others, Value, 2017-2030 (US$ Bn)
FIG. 17 Global Checkpoint Inhibitor Refractory Cancer Market Value Contribution, By Application, 2022 & 2028 (Value %)
FIG. 18 Global Checkpoint Inhibitor Refractory Cancer Market, By Lung Cancer, Value, 2017-2030 (US$ Bn)
FIG. 19 Global Checkpoint Inhibitor Refractory Cancer Market, By Bladder Cancer, Value, 2017-2030 (US$ Bn)
FIG. 20 Global Checkpoint Inhibitor Refractory Cancer Market, By Others, 2017-2030 (US$ Bn)
FIG. 21 U.S. Checkpoint Inhibitor Refractory Cancer Market, 2017-2030 (US$ Bn)
FIG. 22 Canada Checkpoint Inhibitor Refractory Cancer Market, 2017-2030 (US$ Bn)
FIG. 23 Germany Checkpoint Inhibitor Refractory Cancer Market, 2017-2030 (US$ Bn)
FIG. 24 France Checkpoint Inhibitor Refractory Cancer Market, 2017-2030 (US$ Bn)
FIG. 25 U.K. Checkpoint Inhibitor Refractory Cancer Market, 2017-2030 (US$ Bn)
FIG. 26 Italy Checkpoint Inhibitor Refractory Cancer Market, 2017-2030 (US$ Bn)
FIG. 27 Spain Checkpoint Inhibitor Refractory Cancer Market, 2017-2030 (US$ Bn)
FIG. 28 Rest of Europe Checkpoint Inhibitor Refractory Cancer Market, 2017-2030 (US$ Bn)
FIG. 29 China Checkpoint Inhibitor Refractory Cancer Market, 2017-2030 (US$ Bn)
FIG. 30 Japan Checkpoint Inhibitor Refractory Cancer Market, 2017-2030 (US$ Bn)
FIG. 31 India Checkpoint Inhibitor Refractory Cancer Market, 2017-2030 (US$ Bn)
FIG. 32 South Korea Checkpoint Inhibitor Refractory Cancer Market, 2017-2030 (US$ Bn)
FIG. 33 Southeast Asia Checkpoint Inhibitor Refractory Cancer Market, 2017-2030 (US$ Bn)
FIG. 34 Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, 2017-2030 (US$ Bn)
FIG. 35 Latin America Checkpoint Inhibitor Refractory Cancer Market, 2017-2030 (US$ Bn)
FIG. 36 Brazil Checkpoint Inhibitor Refractory Cancer Market, 2017-2030 (US$ Bn)
FIG. 37 Mexico Checkpoint Inhibitor Refractory Cancer Market, 2017-2030 (US$ Bn)
FIG. 38 Rest of Latin America Checkpoint Inhibitor Refractory Cancer Market, 2017-2030 (US$ Bn)
FIG. 39 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market, 2017-2030 (US$ Bn)
FIG. 40 GCC Countries Checkpoint Inhibitor Refractory Cancer Market, 2017-2030 (US$ Bn)
FIG. 41 South Africa Checkpoint Inhibitor Refractory Cancer Market, 2017-2030 (US$ Bn)
FIG. 42 Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, 2017-2030 (US$ Bn)

List of Tables
TABLE 1 Market Snapshot: Global Checkpoint Inhibitor Refractory Cancer Market
TABLE 2 Global Checkpoint Inhibitor Refractory Cancer Market, by Competitive Benchmarking, 2022
TABLE 3 Global Checkpoint Inhibitor Refractory Cancer Market, by Geographical Presence Analysis, 2022
TABLE 4 Global Checkpoint Inhibitor Refractory Cancer Market, by Key Strategies Analysis, 2022
TABLE 5 Global Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
TABLE 6 Global Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
TABLE 7 North America Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
TABLE 8 North America Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
TABLE 9 North America Checkpoint Inhibitor Refractory Cancer Market, by Country, 2017-2030 (US$ Bn)
TABLE 10 US Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
TABLE 11 US Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
TABLE 12 Canada Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
TABLE 13 Canada Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
TABLE 14 Europe Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
TABLE 15 Europe Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
TABLE 16 Europe Checkpoint Inhibitor Refractory Cancer Market, by Country, 2017-2030 (US$ Bn)
TABLE 17 Germany Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
TABLE 18 Germany Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
TABLE 19 France Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
TABLE 20 France Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
TABLE 21 UK Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
TABLE 22 UK Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
TABLE 23 Italy Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
TABLE 24 Italy Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
TABLE 25 Spain Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
TABLE 26 Spain Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
TABLE 27 Rest of Europe Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
TABLE 28 Rest of Europe Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
TABLE 29 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
TABLE 30 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
TABLE 31 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, by Country, 2017-2030 (US$ Bn)
TABLE 32 China Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
TABLE 33 China Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
TABLE 34 Japan Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
TABLE 35 Japan Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
TABLE 36 India Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
TABLE 37 India Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
TABLE 38 South Korea Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
TABLE 39 South Korea Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
TABLE 40 South East Asia Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
TABLE 41 South East Asia Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
TABLE 42 Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
TABLE 43 Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
TABLE 44 Latin America Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
TABLE 45 Latin America Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
TABLE 46 Latin America Checkpoint Inhibitor Refractory Cancer Market, by Country, 2017-2030 (US$ Bn)
TABLE 47 Brazil Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
TABLE 48 Brazil Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
TABLE 49 Mexico Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
TABLE 50 Mexico Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
TABLE 51 Rest of Latin America Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
TABLE 52 Rest of Latin America Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
TABLE 53 Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
TABLE 54 Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
TABLE 55 Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, by Country, 2017-2030 (US$ Bn)
TABLE 56 GCC Countries Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
TABLE 57 GCC Countries Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
TABLE 58 South Africa Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
TABLE 59 South Africa Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)
TABLE 60 Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Type, 2017-2030 (US$ Bn)
TABLE 61 Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Application, 2017-2030 (US$ Bn)

Frequently asked questions

How does COVID-19 Impact the global checkpoint inhibitor refractory cancer market?

The COVID-19 pandemic’s impact on the market has been significant because it immediately stopped needless medical operations

Which is the leading region of the market for checkpoint inhibitor refractory cancer?

North America accounted for the most heightened share market.

What are the key drivers for checkpoint inhibitor refractory cancer market growth?

Increasing lung cancer cases and rise in cancer awareness programs to drive the checkpoint inhibitor refractory cancer market.

Which is the major type segment in the checkpoint inhibitor refractory cancer market?

The CTLA-4 Inhibitor segment had a major share in the global market in 2022.

Which is the major segment in the checkpoint inhibitor refractory cancer market by application?

The lung cancer segment had a major share in the global market.

India Bariatric Surgery Devices Market

Published:
Report ID: 36164

Veterinary Imaging Systems Market

Published:
Report ID: 36104

Bioprosthetics Market

Published:
Report ID: 36087

Antineoplastic Agents Market

Published:
Report ID: 36065

Benign Prostatic Hyperplasia Treatment Market

Published:
Report ID: 36062

US Retail Pharmacy Market

Published:
Report ID: 32801

Cervical Total Disc Replacement Market

Published:
Report ID: 36030

Aseptic Sampling Market

Published:
Report ID: 36018

Capillary Blood Collection Devices Market

Published:
Report ID: 36014

Contrast Media Market

Published:
Report ID: 36005

Medical Adhesive Tapes Market

Published:
Report ID: 35998

OTC Vitamins Dietary Supplements Market

Published:
Report ID: 35994

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN